ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma
Frontiers in Oncology · 21.07.2026 · 16
DOI: 10.3389/fonc.2026.1882429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 21.07.2026. Verfasst von Shaofu Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Medical University School and Hospital of Stomatology, Taiyuan, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Oral squamous cell carcinoma (OSCC) shows marked biological heterogeneity, but markers that connect malignant epithelial states with the tumor immune context remain limited. Origin recognition complex subunit 6 (ORC6) participates in DNA replication licensing, but its disease-specific role in OSCC is not well defined.
Methods
We integrated anatomically filtered bulk transcriptomic data, external validation cohorts, single-cell transcriptomic profiling, immune-context analyses, proliferation-adjusted sensitivity analyses, virtual perturbation, and in vitro ORC6-knockdown assays to evaluate the clinical and biological relevance of ORC6 in OSCC.
Results
After reconstruction of a strictly defined TCGA oral cavity OSCC cohort excluding base of tongue and other non-oral cavity subsites, ORC6 remained upregulated in OSCC tissues and cell lines and was associated with adverse clinicopathological features and poorer survival. Exploratory analysis in the HPV-negative GSE41613 cohort further supported the adverse survival association of ORC6. Single-cell analysis showed preferential enrichment of ORC6 in malignant epithelial cells. Within this compartment, high ORC6 expression marked a replication-active state characterized by activation of DNA-replication and cell-cycle programs and weaker transcriptional signatures of interferon response and antigen presentation. These differences were directionally preserved in donor-matched pseudobulk comparisons and after cell-cycle-score regression. At the bulk-tumor level, proliferation-adjusted models showed that ORC6 retained directionally inverse associations with selected immune-related features, including cytolytic activity, IFN-γ response, and MHC-I/antigen-presentation signatures. ORC6 knockdown in CAL27 cells reduced cell growth, migration, invasion, and S-phase fraction while increasing antigen-presentation-associated transcripts and surface HLA-A/B/C expression.
Discussion
These findings support ORC6 as a marker of a replication-active malignant epithelial state associated with attenuated immune-related features in OSCC, particularly antigen-presentation-related programs. Further functional immune-recognition studies and independent clinical validation are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanxi Medical University School and Hospital of Stomatology, Taiyuan, China.
- The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan, China.
- Shanxi Oral Health Prevention and Control Technology Innovation Center, Taiyuan, China.
Zitieren
APA
Yan, S., Tan, W., Zhang, Y., Si, J., Guo, J., Yang, B., & Shi, J. (2026). ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1882429
Vancouver
Yan S, Tan W, Zhang Y, Si J, Guo J, Yang B, et al. ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1882429
BibTeX
@article{Yan2026,
author = {Yan, Shaofu and Tan, Wenqi and Zhang, Yanxin and Si, Jinyan and Guo, Jiehua and Yang, Bo and Shi, Jing},
title = {ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1882429}
}
EUVIMED